FDA trial shows sustained effect for Ozurdex on diabetic

The dexamethasone intraocular implant OZURDEX® (Allergan)

can bring about significant and visual improvement in patients

with diabetic macular oedema, with generally only transient

increases in IOP but with a high incidence of cataract in

phakic patients, said EURETINA president ,Francesco

Bandello MD, told attendees at an EURETINA free paper

session

He reported the pooled  results of two FDA studies conducted

by the MEAD study group involving a total of 1048 patients 

with diabetic macular oedema. The patients were randomised

into three groups to receive Ozurdex at a dosage of 0.7 mg  or

0.35 mg , or sham treatment, with repeated injections when

indicated at intervals no shorter than six months.